Searching for 'omic' biomarkers

Canadian Journal of Cardiology

Volumn 25, Issue SUPPLA, 2009, Pages 9A-14A

  Lin, David ^a   Hollander, Zsuzsanna ^a   Meredith, Anna ^a   McManus, Bruce M ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Biomarker; Cardiovascular; Genomics

Indexed keywords

BIOLOGICAL MARKER;

CANADA; CARDIOVASCULAR DISEASE; GENETICS; HUMAN; ORGAN TRANSPLANTATION; PHARMACOGENETICS; REPRODUCIBILITY; REVIEW; STANDARD;

BIOLOGICAL MARKERS; CANADA; CARDIOVASCULAR DISEASES; HUMANS; ORGAN TRANSPLANTATION; PHARMACOGENETICS; REPRODUCIBILITY OF RESULTS;

EID: 67649547159     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0828-282X(09)71048-7     Document Type: Conference Paper

References (52)

1. Heart and Stroke Foundation of BC and Yukon. Statistics. (Version current 2008) 2008 www. heartandstroke.bc.ca/site/c.kpIPKXOyFmG/ b.3644453/k.3454/ Statistics.htm.
2. Public Health Agency of Canada. Economic (Version current April 25,burden of illness in Canada, 1998. www.phac-aspc.gc.ca/publicat/ebic-femc98/ 2009).
3. Causes of death, 2004. Released 2006. For provincial and national mortality tables, go to and click on the Statistics Canada link. (Version current at May 11, 2009).http://www.heartandstroke.on.ca/site/c. pvI3IeNWJwE/b.3581729/k.359A/Statistics.htm
4. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clin Pharmacol Ther 2001;69:89-95.
5. Health Canada. Adoption of ICH Guidance: Guidance Document Definitions for Genomic Biomarkers, Pharmacogenomics, Pharmacogenetics, Genomic Data and Sample Coding Categories, ICH Topic E15. 2008 (Version current April 25, 2009).www.hc-sc.gc.ca/dhp-mps/alt_formats/hpfb-dgpsa/pdf/ prodpharma/e15-eng.pdf
6. Moore RE, Kirwan J, Doherty MK, Whitfield PD. Biomarker discovery in animal health and disease: The application of postgenomic technologies. Biomark Insights 2007;2:185-96.
7. Hunt SM, Thomas MR, Sebastian LT, et al. Optimal replication and the importance of experimental design for gel-based quantitative proteomics. J Proteome Res 2005;4:809-19.
8. Lee JW, Figeys D, Vasilescu J. Biomarker assay translation from discovery to clinical studies in cancer drug development: Quantification of emerging protein biomarkers. Adv Cancer Res 2007;96:269-98.
9. Listgarten J, Emili A. Statistical and computational methods for comparative proteomic profiling using liquid chromatography-tandem mass spectrometry. Mol Cell Proteomics 2005;4:419-34.
10. Bast RC Jr, Lilja H, Urban N, et al. Translational crossroads for biomarkers. Clin Cancer Res 2005;11:6103-8.
11. Baker M. In biomarkers we trust? Nat Biotechnol 2005;23:297-304.
12. Benowitz S. Biomarker boom slowed by validation concerns. J Natl Cancer Inst 2004;96:1356-7.
13. FDA. Guidance for Industry: (Version current April 25, 2009). Bioanalytical Method Validation. 2001. www.fda.gov/CDER/GUIDANCE/4252fnl.pdf.
14. FDA. Innovation or Stagnation: Challenge and Opportunity on the Critical Path to New (Version current April 25, 2009). Medical Products. 2004. www.fda.gov/oc/ initiatives/criticalpath/whitepaper.pdf
15. FDA. Guidance for Industry: Pharmacogenomic Data Submissions. (Version current April 25). 2005. www.fda.gov/cber/gdlns/pharmdtasub.pdf.2009
16. Goodsaid F, Frueh F. Biomarker qualification pilot process at the US Food and Drug Administration. AAPS J 2007;9:E105-108.
17. Bonassi, S, Neri M, Puntoni R. Validation of biomarkers as early predictors of disease. Mutat Res 2001;480-481:349-58.
18. Goodsaid F. Impact of the biomarker qualification project on drug development. Critical Markers of Disease Symposium 2008. www. cmod.org/slide_presentations/resources_slides_2008.html. (Version current April 25, 2009).
19. Goodsaid F, Frueh F. Process map proposal for the validation of genomic biomarkers. Pharmacogenomics 2006;7:773-82.
20. Lee JW, et al. Method validation and measurement of biomarkers in nonclinical and clinical samples in drug development: A conference report. Pharm Res 2005;22:499-511.
21. Colburn WA. Biomarkers in drug discovery and development: From target identification through drug marketing. J Clin Pharmaco l2003;43:329-41.
22. Wagner JA, Williams SA, Webster CJ. Biomarkers and surrogate end points for fit-for-purpose development and regulatory evaluation of new drugs. Clin Pharmacol Ther 2007;81:104-7.
23. Ilyin SE, Belkowski SM, Plata-Salaman CR. Biomarker discovery and validation: Technologies and integrative approaches. Trends Biotechnol 2004;22:411-6.
24. Lee JW, et al. Fit-for-purpose method development and validation for successful biomarker measurement. Pharmaceut Res 2006;23:312-28
25. Wagner JA. Overview of biomarkers and surrogate endpoints in drug development. Dis Markers 2002;18:41-6
26. Normolle D, Ruffin Iv MY, Brenner D. Design of early validation trials of biomarkers. Cancer Inform 2005;1:25-31
27. McCormick T, Martin K, Hehenberger M. The evolving role of biomarkers: Focusing on patients from research to clinical practice, in IBM (Imaging) Biomarker Summit III. Nice, France, 2007.
28. Woodcock J, Woosley R. The FDA critical path initiative and its influence on new drug development. Ann Rev Med 2008;59:1-12.
29. Krishna R, Herman G, Wagner JA. Accelerating drug development using biomarkers: A case study with sitagliptin, a novel DPP4 inhibitor for type 2 diabetes. AAPS J 2008;10:401-9.
30. Pratt CM, Moye LA. The cardiac arrhythmia suppression trial. Casting suppression in a different light. Circulation 1995;91:245-7.
31. Hirsh J, et al. American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. J Am Coll Cardiol 2003;41:1633-52.
32. Herman D, et al. Influence of CYP2C9 polymorphisms, demographic factors and concomitant drug therapy on warfarin metabolism and maintenance dose. Pharmacogenomics J 2005;5:193-202.
33. FDA. FDA clears genetic lab test for warfarin sensitivity. 2007. Version current April 25, www.fda.gov/bbs/topics/NEWS/2007/NEW01701.html. 2009).
34. Anderson KM. Clinical uses of brain natriuretic peptide in diagnosing and managing heart failure. J Am Acad Nurse Pract 2008;20:305-10
35. Godkar D, et al. B-type natriuretic peptide (BNP) and proBNP: Role of emerging markers to guide therapy and determine prognosis in cardiovascular disorders. Am J Ther 2008;15:150-6.
36. Zieske LR. A perspective on the use of iTRAQ reagent technology for protein complex and profiling studies. J Exp Bot 2006;57:1501-8
37. Wishart DS. Metabolomics: A complementary tool in renal transplantation. Contrib Nephrol 2008;160:76-87.
38. Karmen A, Wroblewski F, Ladue JS. Transaminase activity in human blood. J Clin Invest 1955;34:126-31.
39. Tillett WS, Francis Jr T. Serological reactions in pneumonia with a nonprotein somatic fraction of pneumococcus. J Exp Med 1930;52:561-85.
40. Elster SK, Braunwald E, Wood HF. A study of C-reactive protein in the serum of patients with congestive heart failure. Am Heart J 1956;51:533-41.
41. Sorensen NS. Creatine phosphokinase in the diagnosis of myocardial infarction. Acta Med Scand 1963;174:725-34.
42. Rogers WJ, McDaniel HG, Smith LR, Mantle JA, Russel RO Jr, Rackley CE. Correlation of angiographic estimates of myocardial infarct size and accumulated release of creatine kinase MB isoenzyme in man. Circulation 1977;56:199-205.
43. Tsung SH. Several conditions causing elevation of serum CK-MB and CK-BB. Am J Clin Pathol 1981;75:711-5.
44. Kisch B. Electron microscopy of the atrium of the heart. I. Guinea pig. Exp Med Surg 1956;14:99-112.
45. de Bold AJ, Borenstein HB, Veress AT, Sonnenberg H. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Life Sci 1981;28:89-94.
46. Burnett JC Jr, Kao PC, Hu DC, et al. Atrial natriuretic peptide elevation in congestive heart failure in the human. Science 1986;231:1145-7.
47. Ebashi S. Third component participating in the superprecipitation of "natural actomyosin". Nature 1963;200:1010.
48. Cummins B, Auckland ML, Cummins P. Cardiac-specific troponin-I radioimmunoassay in the diagnosis of acute myocardial infarction. Am Heart J 1987;113:1333-44.
49. Cummins P, Young A, Auckland ML, Michie CA, Stone PC, Shepstone BJ. Comparison of serum cardiac specific troponin-I with creatine kinase, creatine kinase-MB isoenzyme, tropomyosin, myoglobin and C-reactive protein release in marathon runners: Cardiac or skeletal muscle trauma? Eur J Clin Invest 1987;17:317-24.
50. Mukoyama M, Nakao K, Saito Y, et al. Increased human brain natriuretic peptide in congestive heart failure. N Engl J Med 1990;323:757-8.
51. Morita E, Yasue H, Yoshimura M, et al. Increased plasma levels of brain natriuretic peptide in patients with acute myocardial infarction. Circulation 1993;88:82-91
52. Mansfield E. International Partnership for Critical Markers of Disease. www.cmod.org (Version current at May 12, 2009).